Company Filing History:
11 out of 276 
3 out of 1,537 
Years Active: 2000-2014
Title: **Rajashekhar Betageri: Pioneering Innovator in Pharmaceutical Sciences**
Introduction
Rajashekhar Betageri, based in Bethel, Connecticut, is a notable inventor with a remarkable portfolio of 14 patents. His work primarily focuses on developing advanced pharmaceutical compositions and methods that hold significant implications for treating various medical conditions. His innovative spirit and dedication to research continue to inspire the pharmaceutical industry.
Latest Patents
Among Rajashekhar's latest contributions to science are significant patents related to glucocorticoid mimetics. These involve methods for making pharmaceutical compositions and their applications in modulating glucocorticoid receptor function. The compounds described in his patents, including various formulations (IA, IB, IC, and ID), open new avenues for treating disease-states characterized by inflammatory, allergic, and proliferative processes. Another noteworthy patent pertains to pyrrolidine compounds that modulate the CB2 receptor, acting as agonists and proving beneficial in treating inflammation and pain.
Career Highlights
Rajashekhar Betageri has made substantial contributions during his tenure at prominent companies such as Boehringer Ingelheim Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. His experience and expertise in drug development have not only led to his patent inventions but have also contributed to the advancement of pharmaceutical science.
Collaborations
Throughout his career, Rajashekhar has collaborated with distinguished colleagues, including John Robert Proudfoot and David S. Thomson. These partnerships have fostered a collaborative environment that nurtures innovation and the sharing of ideas critical to enhancing medical treatments.
Conclusion
In summary, Rajashekhar Betageri exemplifies the role of inventors in developing groundbreaking pharmaceutical solutions. With 14 patents to his name, including innovative compounds that target critical receptors, he continues to impact the field significantly. His career at leading pharmaceutical companies, along with valuable collaborations, marks him as a key figure in contemporary drug development, paving the way for future innovations in healthcare.